Oncology biopharmaceutical company BerGenBio has been granted a GBP 1.6 million seeding drug discovery award from the UK's Wellcome Trust. The money will go to develop novel small molecule inhibitors against BGB002, its proprietary, novel cancer target. BGB002 controls tumour cell malignantAlready a subscriber Login You have read all your free articles, to continue reading subscribe…